Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Roth Conference 2015
25 slides from Prescient Therapeutics's conference presentation, Mar 10, 2015
Slide 1: Roth Conference
For personal use only Roth Conference March 8-11, 2015 Dr. Rob Crombie Managing Director
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor Certain statements made in this presentation are forward-looking statements within the meaning of the safe harbour provisions of the United For personal use only States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical fa
Slide 3: Investment Highlights
Investment Highlights For personal use only 2 small molecule drug candidates targeting key cancer pathways, AKT Novel Technology (PTX-200) and Ras (PTX-100) Multiple Shots on 5 clinical trials: 2 underway and 3 on track to initiate within 12 months Goal Multiple milestone announcements and valuation
Slide 4: Developing Two Novel Cancer Compounds
Developing Two Novel Cancer Compounds For personal use only • PTX 100 – Blocks Ras signalling pathway • PTX 200 – Blocks AKT signalling pathway • Both pathways mediate chemotherapy resistance • Multi-pronged approach to breaking chemotherapy resistance 4
Slide 5: Clinical Trials Recruiting & Planned for 2015
Clinical Trials Recruiting & Planned for 2015 For personal use only Targeting AKT & Ras Cancer Pathways Phase Phase Phase Phase Phase 1b/2 1b 1b/2 1b/2 1b/2 Acute Breast Multiple Breast Ovarian Myeloid Cancer Myeloma Cancer Cancer Leukemia PTX-200 (TCN-P) PTX-200 (TCN-P) PTX-200 (TCN-P) PTX-100 (GGT
Slide 6: Market Opportunity - Prescient
Market Opportunity - Prescient For personal use only • Chemotherapy resistance – Primary cause of failure of existing chemotherapy treatments – Critical unmet need for new agents • Prescient’s oncology drug candidate development strategy – Developing therapies to overcome resistance by switching off
Slide 7: PTX-200: Summary
PTX-200: Summary For personal use only • Activated AKT plays key role in many cancers including breast, ovarian, colorectal, prostate, pancreatic and hematologic cancers • Strong interest in AKT as a drug PTX-200 (TCN-P) target • PTX-200 inhibits AKT pathway & overcomes resistance to chemotherapeuti
Slide 8: PTX-200: Mechanism of Action
PTX-200: Mechanism of Action AKT is an ON/OFF switch that controls normal cell division AKT is ON when phosphorylated and OFF when not For personal use only Resting/non-dividing Cell Dividing Cell Akt moves to cell membrane where it gets phosphorylated P and activated to stimulate cell division Rece
Slide 9: PTX-200: Mechanism of Action
PTX-200: Mechanism of Action Some cancer cells contain Akt that is always phosphorylated* stimulating cells to divide forever Akt is ON when phosphorylated and OFF when not For personal use only Untreated Cancer Cell Dividing Cell Akt is stuck in PTX-200 prevents AKT the ON position membrane interac
Slide 10: PTX-200: Extensive Clinical Experience
PTX-200: Extensive Clinical Experience For personal use only • Phase 1 programs Completed: H Lee Moffitt & MD Anderson – Library screen identified PTX-200 as a potent AKT inhibitor – Evaluated in Acute Leukemia and Solid tumor clinical studies – PTX-200 shown to decrease pAKT levels in tumors – Acut
Slide 11: PTX-200: Ongoing Clinical Studies
PTX-200: Ongoing Clinical Studies • Breast Cancer – PTX-200 plus Taxol in patients with For personal use only metastatic and locally advanced breast cancer – Recruiting at Albert Einstein College of Medicine Montefiore Medical Center – Funded by National Cancer Institute grant Dr Joseph Sparano, Pri
Slide 12: PTX-200: Proposed Phase 1b/2 Acute Myeloid Leukemia Clinical Program
PTX-200: Proposed Phase 1b/2 Acute Myeloid Leukemia Clinical Program For personal use only . • Phase Ib/2 PTX-200 plus cytarabine in refractory or relapsed acute leukemia – Protocol in place; ready to initiate H1 2015 Dr Jeffrey E Lancet MD, – Refractory patients in combination with cytarabine Princ
Slide 13: PTX-100: Summary
PTX-100: Summary For personal use only • Small molecule inhibitor of the Ras signaling pathway • Invented at Yale University and Moffitt Cancer Center • Blocks important cancer growth PTX-100 (GGTI) enzyme geranylgeranyl transferase • Phase 1 trials demonstrated it is well tolerated, patients achiev
Slide 14: PTX-100: Mechanism of Action
PTX-100: Mechanism of Action Ras and Ral are ON/OFF switches that control normal cell division For personal use only Resting/non-dividing Cell Dividing Cell GGT-1 adds GG to Ral. GG and Ral go from OFF to F F ON which contributes to Receptor Receptor cell division GGT-1 Ras Ras GGT-1 GG GG GDP GTP R
Slide 15: PTX-100: Mechanism of Action
PTX-100: Mechanism of Action Ral requires geranylgeranylation (GG) to cause cancer For personal use only Untreated Cancer Cell Dividing Cell Some cancer cells contain Ras PTX-1– Binds to GGT-1 and and Ral that are always in the prevents GGT-1 from adding ON GTP position GG to Ral, blocking it F F Re
Slide 16: PTX-100: Phase Completed
PTX-100: Phase 1 Completed For personal use only Patients 13 Trial Centers Patient Inclusion Advanced solid tumors for which standard treatments failed – “refractory” Methods PTX-100 as a 30-min IV infusion on Days 1-5 every 21 days • Determine dose limiting toxicity (DLT) Study Objectives • Assess
Slide 17: PTX-100: Planned Trials
PTX-100: Planned Trials For personal use only Phase 1b/2 Multiple Myeloma Phase 1b Breast Cancer • High mortality rate, large unmet • High unmet medical need for medical need advanced disease • Phase 1b dose escalation in >18 • Phase 1b dose escalation in patients to determine safe & patients with m
Slide 18: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio For personal use only PTX-100 PTX-200 • Strong Composition of Matter patent • IP estate anchored by covering “Piperazinone compounds as “foundational” patent issued Jan anti-tumor and anti-cancer agents & 2013 methods of treatment” • Established PTX-200 as a ta
Slide 19: Executive Management
Executive Management For personal use only Rob Crombie • 18 years in private and public biotech in the UK and Australia Managing Director - Significant business development track record of closing deals between biotechnology and pharma • Formerly head of Melbourne operations at Arana Therapeutics -
Slide 20: Board of Directors & Scientific Advisory Board
Board of Directors & Scientific Advisory Board For personal use only Steve Engle • Former Chairman and CEO of US-listed XOMA (NASDAQ:XOMA) and La Non-Executive Jolla Pharmaceuticals (NASDAQ: LJPC) Chairman • Currently CEO of Averigon Consulting, an advisory firm to life science industry Dr. James •
Slide 21: Multiple Milestones Over Next 12-18 Months
Multiple Milestones Over Next 12-18 Months For personal use only 2014 2015 2016-17 PTX-200 Initiate Phase 1b (Ovarian) 2 ✓ PTX-200 Complete Phase 1b (Breast)1 PTX-100 Reactivate Breast IND PTX-100 File IND for Multiple Myeloma PTX-200 Initiate Phase 2(Breast)1 PTX-200 Complete Phase 1b (Ovarian) PTX
Slide 22: Financial Summary
Financial Summary For personal use only Key Metrics Shareholder Base ASX Ticker PTX Board + Share Price1 A$0.11 Mgmt. Yale 18% University, Market Cap1 A$5.5 million 2% Cash Position2 A$2.3 million Total Issued Capital 52 million shares Options 87 million @ A$0.05 Top 20 Own 33% Retail 80% Average Da
Slide 23: Market Caps of Oncology Companies at a Similar Stage
Market Caps of Oncology Companies at a Similar Stage For personal use only Lead Product Number of Market Cap Company Exchange Status Products $ USD mm Helix Biopharma TSX:HBP Phase 2 2 111 Coronado Biosciences NASDAQ:CNDO Phase 2 2 123 VBL Therapeutics NASDAQ:VBLT Phase 2 2 73 Provectus NYSE:PVCT Ph
Slide 24: Why Prescient?
Why Prescient? For personal use only Novel Technologies Multiple Shots on Goal News Flow Robust IP Proven Leadership & Management Significant Investment to Date Leveraging Resources 24
Slide 25: Contact
For personal use only Contact Dr. Rob Crombie Managing Director Robert.Crombie@PrescientTherapeutics.com +61 439 361 331